Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2018 Dec 5;4(6):e294.
doi: 10.1212/NXG.0000000000000294. eCollection 2018 Dec.

Brain somatic mutations in SLC35A2 cause intractable epilepsy with aberrant N-glycosylation

Nam Suk Sim  1 , Youngsuk Seo  1 , Jae Seok Lim  1 , Woo Kyeong Kim  1 , Hyeonju Son  1 , Heung Dong Kim  1 , Sangwoo Kim  1 , Hyun Joo An  1 , Hoon-Chul Kang  1 , Se Hoon Kim  1 , Dong-Seok Kim  1 , Jeong Ho Lee  1
Affiliations

Brain somatic mutations in SLC35A2 cause intractable epilepsy with aberrant N-glycosylation

Nam Suk Sim et al. Neurol Genet. .

Abstract

Objective: To identify whether somatic mutations in SLC35A2 alter N-glycan structures in human brain tissues and cause nonlesional focal epilepsy (NLFE) or mild malformation of cortical development (mMCD).

Methods: Deep whole exome and targeted sequencing analyses were conducted for matched brain and blood tissues from patients with intractable NLFE and patients with mMCD who are negative for mutations in mTOR pathway genes. Furthermore, tissue glyco-capture and nanoLC/mass spectrometry analysis were performed to examine N-glycosylation in affected brain tissue.

Results: Six of the 31 (19.3%) study patients exhibited brain-only mutations in SLC35A2 (mostly nonsense and splicing site mutations) encoding a uridine diphosphate (UDP)-galactose transporter. Glycome analysis revealed the presence of an aberrant N-glycan series, including high degrees of N-acetylglucosamine, in brain tissues with SLC35A2 mutations.

Conclusion: Our study suggests that brain somatic mutations in SLC35A2 cause intractable focal epilepsy with NLFE or mMCD via aberrant N-glycosylation in the affected brain.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Representative radiologic and pathologic images of patients with brain somatic mutations in SLC35A2
(A) Preoperative and postoperative brain MRI T2-weighted images from patients EPI219 and LGS150 with brain somatic mutations in SLC25A2. These T2-weighted images demonstrate no remarkable findings in the brain parenchyma, including the temporal lobe. Yellow arrowhead: putative regions of epileptic focus. (B) Histopathologic images from H & E staining and immunohistochemical (IHC) staining from EPI219 (upper panels) and LGS150 (lower panels) brain tissues. Black arrowheads: scattered neuron in white matter. Scale bars, 40 μm in H & E staining and 200 μm in IHC staining for NeuN, a neuronal marker (C) Capture image from integrative genomic viewer (IGV) (upper panels), showing the results of site-specific amplicon sequencing. Schematic tables (lower panels) showing the number of sequence reads counted as mutated or reference sequences, as well as the VAFs of mutated alleles. Mut: mutation, Ref: reference.
Figure 2
Figure 2. Patient brain tissues with somatic mutations in SLC35A2 encoding a UDP-galactose transporter exhibiting aberrant N-glycosylation
(A) Schematic figure showing brain somatic mutations in SLC35A2 identified in this study. Red star: locations of each identified mutation (B) Extracted compound chromatograms (ECCs) of N-glycans from brain tissues. EPI219 and LGS150: subjects carrying somatic mutations in SLC35A2. Control EPI166: patient with intractable focal epilepsy confirmed to have no specific somatic or germline mutations in deep WES. Control MET886 and MET344: specimens from the tumor-free margin of individuals with a metastatic tumor as part of a planned resection. These specimens were pathologically confirmed as normal brain tissue. The ECCs were color coded according to N-glycosylation types: blue for complex-type glycans containing galactose residues, red for truncated-type glycans, green for high mannose glycans, sky blue for hybrid-type glycans, and pink for the glycans involving high degrees of HexNAc residues. Pink round rectangle square: N-glycan structures showing high degrees of N-acetylglucosamine (HexNAc), such as Hex3HexNAc7Fuc1 and Hex3HexNAc8Fuc1 (C) Representative CID MS/MS spectrum of aberrant N-glycan Hex3HexNAc7Fuc1 in the positive ion detection mode. Almost all fragment ions were single-protonated ions [M + H]+; others are indicated as a superscript. Pink square: Hex3HexNAc7Fuc1 glycan, identified by collision-induced dissociation MS/MS, representing the ion at M/Z 1036.90.
See this image and copyright information in PMC

Similar articles

  • Somatic SLC35A2 variants in the brain are associated with intractable neocortical epilepsy.
    Winawer MR, Griffin NG, Samanamud J, Baugh EH, Rathakrishnan D, Ramalingam S, Zagzag D, Schevon CA, Dugan P, Hegde M, Sheth SA, McKhann GM, Doyle WK, Grant GA, Porter BE, Mikati MA, Muh CR, Malone CD, Bergin AMR, Peters JM, McBrian DK, Pack AM, Akman CI, LaCoursiere CM, Keever KM, Madsen JR, Yang E, Lidov HGW, Shain C, Allen AS, Canoll PD, Crino PB, Poduri AH, Heinzen EL. Winawer MR, et al. Ann Neurol. 2018 Jun;83(6):1133-1146. doi: 10.1002/ana.25243. Epub 2018 May 16. Ann Neurol. 2018. PMID: 29679388 Free PMC article.
  • Dissecting the genetic basis of focal cortical dysplasia: a large cohort study.
    Baldassari S, Ribierre T, Marsan E, Adle-Biassette H, Ferrand-Sorbets S, Bulteau C, Dorison N, Fohlen M, Polivka M, Weckhuysen S, Dorfmüller G, Chipaux M, Baulac S. Baldassari S, et al. Acta Neuropathol. 2019 Dec;138(6):885-900. doi: 10.1007/s00401-019-02061-5. Epub 2019 Aug 23. Acta Neuropathol. 2019. PMID: 31444548 Free PMC article.
  • Clinical Features, Neuropathology, and Surgical Outcome in Patients With Refractory Epilepsy and Brain Somatic Variants in the SLC35A2 Gene.
    Barba C, Blumcke I, Winawer MR, Hartlieb T, Kang HC, Grisotto L, Chipaux M, Bien CG, Heřmanovská B, Porter BE, Lidov HGW, Cetica V, Woermann FG, Lopez-Rivera JA, Canoll PD, Mader I, D'Incerti L, Baldassari S, Yang E, Gaballa A, Vogel H, Straka B, Macconi L, Polster T, Grant GA, Krsková L, Shin HJ, Ko A, Crino PB, Krsek P, Lee JH, Lal D, Baulac S, Poduri A, Guerrini R; SLC35A2 Study Group. Barba C, et al. Neurology. 2023 Jan 31;100(5):e528-e542. doi: 10.1212/WNL.0000000000201471. Epub 2022 Oct 28. Neurology. 2023. PMID: 36307217 Free PMC article.
  • Brain Mosaicism in Epileptogenic Cortical Malformations.
    Ribierre T, Baulac S. Ribierre T, et al. In: Noebels JL, Avoli M, Rogawski MA, Vezzani A, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies. 5th edition. New York: Oxford University Press; 2024. Chapter 43. In: Noebels JL, Avoli M, Rogawski MA, Vezzani A, Delgado-Escueta AV, editors. Jasper's Basic Mechanisms of the Epilepsies. 5th edition. New York: Oxford University Press; 2024. Chapter 43. PMID: 39637218 Free Books & Documents. Review.
  • Brain Somatic Mutations in Epileptic Disorders.
    Koh HY, Lee JH. Koh HY, et al. Mol Cells. 2018 Oct 31;41(10):881-888. doi: 10.14348/molcells.2018.0247. Epub 2018 Oct 10. Mol Cells. 2018. PMID: 30352490 Free PMC article. Review.
See all similar articles

Cited by

See all "Cited by" articles

References

    1. Duncan JS, Sander JW, Sisodiya SM, Walker MC. Adult epilepsy. Lancet 2006;367:1087–1100. - PubMed
    1. Schuele SU, Lüders HO. Intractable epilepsy: management and therapeutic alternatives. Lancet Neurol 2008;7:514–524. - PubMed
    1. Epi4K consortium; Epilepsy Phenome/Genome Project. Ultra-rare genetic variation in common epilepsies: a case-control sequencing study. Lancet Neurol 2017;16:135–143. - PubMed
    1. Epi4K consortium; Epilepsy Phenome/Genome Project; Allen AS, Berkovic SF, Cossette P, et al. . De novo mutations in epileptic encephalopathies. Nature 2013;501:217–221. - PMC - PubMed
    1. Blümcke I, Thom M, Aronica E, et al. . The clinicopathologic spectrum of focal cortical dysplasias: a consensus classification proposed by an ad hoc task force of the ILAE diagnostic methods commission. Epilepsia 2011;52:158–174. - PMC - PubMed